Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website http://australasianmelanoma.org/

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

Are Thin, Early-Stage Nodular Melanomas Really Low-Risk?

Source: Cancer Network, June 2019 Even thin T1 nodular primary melanomas are associated with “a constellation of aggressive characteristics” that might worsen patient prognosis compared with superficial spreading melanoma, according to findings from an international study published in the Journal of the National Cancer Institute. The findings challenge longstanding assumptions about the life-threatening aggressiveness of nodular melanomas. Nodular […]

READ MORE >

Posted in Melanoma News, Health Professionals, Patients, Latest News, Of Interest

Report Reveals Immunotherapy is the Most Prominent Topic in Melanoma Research Globally

Source: Targeted Oncology, June 2019 Approximately one-third to one-half of patients with advanced melanoma respond to PD-1 inhibitor therapy, which is superior to response rates observed with systemic chemotherapy or even single-agent ipilimumab (Yervoy)—a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocker and the first checkpoint inhibitor approved for melanoma.1-4Nevertheless, a significant proportion of patients have primary, or […]

READ MORE >

Posted in Melanoma News, Patients, Latest News

Dr. Daud Discusses the Immunogenicity of Melanoma

Source: OncLive, June 2019 Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma. Melanoma stands out compared with other solid tumors in terms of its immunogenicity, Daud says. For years, patients with melanoma were treated with […]

READ MORE >

Posted in Melanoma News, Health Professionals, Video Reports

Melanoma Investigators Strive to Overcome PD-1 Inhibitor Resistance

Source: Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma. Melanoma stands out compared with other solid tumors in terms of its immunogenicity, Daud says. For years, patients with melanoma were treated with interleukin-2 and interferon […]

READ MORE >

Posted in Melanoma News, Health Professionals, Video Reports